China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate and Ozagrel Sodium to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide to treat edema diseases; and Candesartan for hypertension. It also provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. In addition, the company offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Further, it provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. The company offers its products through distributors, as well as through its network of 16 sales offices and approximately 1,000 sales representatives. China Pharma Holdings, Inc. was founded in 1993 and is based in Haikou, the People's Republic of China.
IPO Year:
Exchange: AMEX
Website: chinapharmaholdings.com
HAIKOU, China, April 4, 2025 /PRNewswire/ -- China Pharma Holdings Inc. ("China Pharma" or the "Company") (NYSE:CPHI) reported that it expects to implement a 1-for-10 reverse stock split on its common stock effective Tuesday, April 15, 2025, with trading to begin on a split-adjusted basis at the market open on that day. Trading in the common stock will continue on the NYSE American under the symbol "CPHI". The new CUSIP number for the common stock following the reverse stock split is 16941T 401. The reverse stock split at a ratio ranges between 1:10 and 1:20 was authorized by the Company's Board of Directors (the "Board") through unanimous written consent on October 22, 2024 and adopted by
HAIKOU, China, Dec. 18, 2024 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE:CPHI) ("China Pharma", the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced successful completion of all redemptions under its Convertible Promissory Note agreement (the "Convertible Promissory Note") with Streeterville Capital, LLC as of December 11, 2024. This marks a significant step in strengthening the company's financial position and reflects its commitment to sound fiscal management. The Convertible Promissory Note was originally issued on November 17, 2021, with a principal amount of $5,250,000. Following a
HAIKOU, China, Dec. 13, 2024 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE:CPHI) ("China Pharma," or the "Company"), a specialty pharmaceutical company, today announced that it has filed a prospectus supplement with the U.S. Securities and Exchange Commission (the "SEC") under which the Company may offer and sell from time to time shares of common stock, par value $0.001 per share (the "Common Stock"), with an aggregate offering price of up to $600,000 (the "Financing"). The shares will be offered pursuant to a certain Securities Purchase Agreement (the "SPA") the Company entered into with certain investor (the "Investor") on December 12, 2024. Pursuant to the SPA, the Investor agrees t
HAIKOU, China, Aug. 19, 2024 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE:CPHI) ("China Pharma", or the "Company"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced that through Hainan Helpson Medical and Biotechnology Co., Ltd. ("Helpson"), our wholly owned subsidiary, it expects to launch its Dry Eye Disease Therapeutic Device in the first quarter of 2025 in China. It is a medical treatment device for dry eye disease under patent protection;The Company, through Helpson, acquired the technology at the end of 2022 and has subsequently carried out the corresponding commercialization, as well as the registrat
HAIKOU, China, Feb. 23, 2024 /PRNewswire/ -- China Pharma Holdings Inc. ("China Pharma" or the "Company") (NYSE:CPHI) reported that it expects to implement a 1-for-5 reverse stock split on its common stock effective Wednesday, March 6, 2024, with trading to begin on a split-adjusted basis at the market open on that day. Trading in the common stock will continue on the NYSE American under the symbol "CPHI". The new CUSIP number for the common stock following the reverse stock split is 16941T-302. The reverse stock split at a ratio of 1-for-5 shares was approved by the Company's Board of Directors through unanimous written consent on October 16, 2023 and adopted by the Company's stockholders
HAIKOU, China, Nov. 29, 2023 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE:CPHI) ("China Pharma", or the "Company"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced that its Dry Eye Disease (DED) therapeutic device has passed third-party testing and is preparing to apply for market launch to the National Medical Products Administration (NMPA) of China. According to a disclosure by the Shanghai Public Health Clinical Center on June 6, 2023, an epidemiological survey of DED showed that approximately 344 million patients are suffering from DED worldwide, accounting for 30% of the total number of ophthalmic out
HAIKOU, China, Aug. 9, 2023 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE:CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced that its wholly-owned subsidiary Hainan Helpson Medical & Biotechnology Co., Ltd. (hereinafter referred to as "Helpson") has received the "Drug Supplementary Application Approval Notice" for its candesartan tablets by National Medical Products Administration of China (hereinafter referred to as NMPA"), indicating that the Company's candesartan tablets have passed the quality and efficacy consistency evaluation of generic drugs. The consistency evaluation of generic drugs evaluates approved generic drugs based on the p
HAIKOU, China, Feb. 24, 2023 /PRNewswire/ -- China Pharma Holdings Inc. ("China Pharma" or the "Company") (NYSE:CPHI) reported that it expects to implement a 1-for-10 reverse stock split on its common stock effective Monday, March 6, 2023, with trading to begin on a split-adjusted basis at the market open on that day. Trading in the common stock will continue on the NYSE American under the symbol "CPHI". The new CUSIP number for the common stock following the reverse stock split is 16941T-203. The reverse stock split at a ratio of 1-for-10 shares was approved by the Company's Board of Directors through unanimous written consent and the Company's stockholders through Annual Meeting for the fi
HAIKOU, China, Dec. 28, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE:CPHI) ("China Pharma", the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced the launch of N95 medical protective mask ("N95 mask"). On December 26, Hainan Medical Products Administration issued the Registration Certificate of N95 medical protective masks to Hainan Helpson Medical & Biotechnology Co., Ltd., providing a strong material guarantee for further optimizing the industrial layout, production capacity and reserves of epidemic prevention materials in Hainan Province. N95 Mask is a medical-level protection ma
HAIKOU, China, Dec. 15, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE:CPHI) ("China Pharma", the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced that its drugs were listed in The Catalogue of Medicines for People Infected with COVID-19 (First Edition) (hereinafter referred to as the Catalogue) published by People's Daily on December 12, 2022. Recently, China has completely ended its strict quarantine and zero case policies in response to COVID-19 pandemic in the past three years. Out of concern about the spread of the epidemic, people began to hoard many related drugs. The Chinese
10-Q - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
8-K - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
10-K - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
8-K - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
8-K - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
8-K - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
424B5 - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
10-Q - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
DEF 14A - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
PRE 14A - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
3 - CHINA PHARMA HOLDINGS, INC. (0001106644) (Issuer)
4 - CHINA PHARMA HOLDINGS, INC. (0001106644) (Issuer)
3 - CHINA PHARMA HOLDINGS, INC. (0001106644) (Issuer)
4 - CHINA PHARMA HOLDINGS, INC. (0001106644) (Issuer)
HAIKOU, China, Dec. 5, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE:CPHI) ("China Pharma", the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced the Acquisition of Dry Eye Disease Therapeutic Device Project. This device has a patentEpidemiological research shows that the incidence rate of DED is about 25% to 30%, and the incidence rate of people over 65-year-old is 75% in ChinaAccording to the Research Report on the Market Status of the Global Dry Eye Disease Drug Industry in 2022(1), the market size of DED drugs in China in 2021 was approximately RMB3.85 billion (approximately US$0.5
SC 13G - CHINA PHARMA HOLDINGS, INC. (0001106644) (Subject)
SC 13G/A - CHINA PHARMA HOLDINGS, INC. (0001106644) (Subject)
SC 13G - CHINA PHARMA HOLDINGS, INC. (0001106644) (Subject)
SC 13G/A - CHINA PHARMA HOLDINGS, INC. (0001106644) (Subject)
SC 13G - CHINA PHARMA HOLDINGS, INC. (0001106644) (Subject)